 |
| |||
| ||||
|
| |||
|
| ||||
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No | Ctr | Title | PubDate | Int.Class | Appl.No | Applicant | Inventor | ||||
| 1. | US | 20070207992 - Geldanamycin derivatives and method of use thereof | 06.09.2007 |
| 11708226 | Board of Trustees of Michigan State University | Wenkert David | ||||
The present invention relates to novel geldanamycin derivatives which have antitumor and antiparasitic properties. The geldanamycin derivatives disclosed herein have antitumor properties in humans due to their interaction with human heat shock protein 90 (hsp90). The human parasites Plasmodium falciparum, Trypanosoma Cruzi, and Leishmania donovani are lethally susceptible to exposure to geldanamycin via complexation of geldanamycin with their homologs (Pfhsp90, hsp83, and hsp90, respectively) of the human hsp90. The geldanamycin derivatives disclosed herein also interact with these parasitic hsp90 homologs so as to have antiparasitic properties. | |||||||||||
| 2. | WO | WO/2007/098229 - GELDANAMYCIN DERIVATIVES AND METHOD OF USE THEREOF | 30.08.2007 |
| PCT/US2007/004559 | MICHIGAN STATE UNIVERSITY | WENKERT, David | ||||
The present invention relates to novel geldanamycin derivatives which have antitumor and antiparasitic properties. The geldanamycin derivatives disclosed herein have antitumor properties in humans due to their interaction with human heat shock protein 90 (hsp90). The human parasites Plasmodium falciparum, Trypanosoma Cruzi, and Leishmania donovani are lethally susceptible to exposure to geldanamycin via complexation of geldanamycin with their homologs (Pfhsp90, hsp83, and hsp90, respectively) of the human hsp90. The geldanamycin derivatives disclosed herein also interact with these parasitic hsp90 homologs so as to have antiparasitic properties.
| |||||||||||
| 3. | US | 6410028 - Therapeutic and prophylactic methods using heat shock proteins | 25.06.2002 |
| 09372022 | Fordham University | Srivastava, Pramod K. | ||||
The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided. | |||||||||||
| 4. | ZA | 1996/07758 - THERAPEUTIC AND PROPHYLACTIC METHODS USING HEAT SHOCK PROTEINS | 28.05.1997 |
| 1996/07758 | FORDHAM UNIVERSITY | SRIVASTAVA PRAMOD K | ||||
The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenou antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Method of prevention and treatment of cancer and infectious disease are provided.
| |||||||||||
| 5. | EP | 1604684 - Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens | 14.12.2005 |
| 05000374 | SINAI SCHOOL MEDICINE | SRIVASTAVA PRAMOD K | ||||
|
| |||||||||||
| 6. | WO | WO/2001/072779 - CHARACTERIZATION OF GRP94-LIGAND INTERACTIONS AND PURIFICATION, SCREENING, AND THERAPEUTIC METHODS RELATING THERETO | 04.10.2001 |
| PCT/US2001/009512 | DUKE UNIVERSITY | NICCHITTA, Christopher, V. | ||||
The present invention discloses characterization of interactions between ligands and Hsp90 proteins, including GRP94, wherein ligand binding to the N-terminal nucleotide binding domain of GRP94 elicits a conformational change that converts the GRP94 from an inactive to an active conformation, and wherein the chaperone and peptide-binding activities of the GRP94 are markedly stimulated. Also disclosed are purification, screening, and therapeutic methods pertaining to the biological activity of GRP94, and in some instances HSP90, based upon the characterization of ligand interactions of Hsp90 peptide-binding proteins, including GRP94.
| |||||||||||
| 7. | US | 6461615 - Therapeutic and prophylactic methods using heat shock proteins | 08.10.2002 |
| 09545351 | Fordham University | Srivastava, Pramod K. | ||||
The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided. | |||||||||||
| 8. | US | 20030035808 - Therapeutic and prophylactic methods using heat shock proteins | 20.02.2003 |
| 10265505 | Fordham University | Srivastava Pramod K. | ||||
The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided. | |||||||||||
| 9. | US | 20060078563 - Using heat shock proteins to increase immune response | 13.04.2006 |
| 11283102 | University of Connecticut Health Center | Srivastava Pramod K. | ||||
The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which are then introduced into a subject in conjunction with a vaccine. The HSPs used in the methods of the invention can be unbound or can be covalently or noncovalently bound to a peptide that is unrelated to the vaccine. The subject is preferably mammalian, and most preferably human. It is shown by way of example herein that HSPs induces secretion of cytokines and surface expression of antigen-presenting and co-stimulatory molecules. The invention also encompasses methods of treatment and prevention of cancer and infectious diseases in a subject. | |||||||||||
| 10. | US | 6455503 - Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens | 24.09.2002 |
| 09412420 | Mount Sinai School of Medicine of New York University | Srivastava, Pramod K. | ||||
Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative to initiate in the mammal a cytotoxic T cell response against cells infected with a preselected intracellular pathogen. Also disclosed are methodologies for preparing and administering vaccines containing such stress protein-peptide complexes. | |||||||||||
